Get Started

DTIL

NASD Precision BioSciences, Inc.
Nov 6, 2026 · 9:14 AM ET LAST TRADE Market Closed

$10.09 ↑ +0.22 (+2.23%) Trading Up from the previous close of $9.87

YTD change
+142.55%
vs 20-day SMA
+47.00%
vs 200-day SMA
+52.48%

Price ranges

Previous day
$8.40 $11.29
open $8.49 close $9.87
+$1.38 (+16.25%)
Today
$0.00 $0.00
$10.09
Past week
$6.64 $11.29
from $7.44 now $10.09
+$2.65 (+35.62%)
Past month
$5.72 $11.29
from $6.43 now $10.09
+$3.66 (+56.92%)
This year
$3.53 $11.29
from $4.16 now $10.09
+$5.93 (+142.55%)

Price & Performance

+2.35 (+31.25%) / 6M

$5.44$7.03$8.61$10.20May 6Aug 6Nov 5

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 98.6% away from all-time highs of $710.11
  • DTIL is up 143% since the beginning of the year
  • DTIL is up 57% over the past 12 months
  • DTIL is up 57% over the past 1 month
  • 5% of all DTIL investors are betting against DTIL

DTIL reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +53.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.28
Earnings momentum +60.5% Quarterly EPS growth
Quarterly change +60.5%

Valuation

P/E ratio 28.00
Enterprise value $216.6M
Beta 1.70

Balance sheet & scale

IncomeN/A
Revenue$45.0M
Cash$81.8M
Debt$27.7K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $444.7M

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $460.28 -3.80%
MRNA Moderna, Inc. $241.46 -6.55%
RVMD Revolution Medicines, Inc. $177.65 -11.04%
ROIV Roivant Sciences Ltd. $36.62 -4.21%
BNTX BioNTech SE Sponsored ADR $85.86 -5.34%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.